PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Urban, Stephan
TI  - Myrcludex B Therapy Reduced HBV DNA and HDV RNA in Phase 2a Clinical Trial
DP  - 2014  01
TA  - MD Conference Express
PG  - 19--20
VI  - 14
IP  - 48
4099  - http://mdc.sagepub.com/content/14/48/19.short
4100  - http://mdc.sagepub.com/content/14/48/19.full
AB  - Chronic hepatitis B virus (HBV) infection is rarely cured with current therapies, and there is no effective therapy for hepatitis D virus (HBD) coinfection. Myrcludex B is a first-in-class entry inhibitor that inactivates the HBV and HDV receptor sodium taurocholate cotransporting polypeptide. This article discusses a phase 2a study evaluating the safety, tolerability, and antiviral efficacy of Myrcludex B.